Literature DB >> 16234450

Mortality following exenteration for malignant tumours of the orbit.

I Rahman1, A Maino, A E Cook, B Leatherbarrow.   

Abstract

BACKGROUND: Orbital exenteration is a rare, but disfiguring procedure reserved for the treatment of locally invasive malignancy or potentially life threatening orbital neoplasms, when less destructive techniques are inadequate. The authors report their experience and analyses of 64 cases of orbital exenteration performed over a 13 year period, looking specifically at key factors affecting mortality associated with such a destructive surgical procedure.
METHODS: Records were reviewed retrospectively of all patients who had undergone exenteration of the orbit from 1 January 1991 to 1 April 2004 inclusive, at the Manchester Royal Eye Hospital. In all cases of deceased individuals, the cause of death was determined by liaison with the general practitioner and local health authority. Duplicate death certificates were requested for all deceased patients from the Registrar for Births, Deaths, and Marriages, Southport, UK. Kaplan-Meier analysis was used to estimate survival following exenteration.
RESULTS: Overall, 1 year survival post-exenteration was high at 93%. After 3 years this had fallen to 67%, followed by 57% after 5 years, and 37% at 10 years. 13 patients died as a direct result of the orbital tumour. A further nine died of unrelated medical conditions, and two patients succumbed to malignant processes originating elsewhere in the body. There was no difference in survival rate at 3 years (p=0.99) and 5 years (p=0.454) between those with clear resection margins and those without.
CONCLUSION: In this study it was found that there was an overall mortality rate of 38% over 12 years. The presence of clear surgical margins, although reassuring for the surgeon, should not be regarded as an indication of cure. However, an overall 1 year survival of 93% and a 10 year survival of 37% are reassuring in that a proportion of individuals achieve surgical cure following exenteration. 38% of patients died as a result of other medical causes over the 12 year follow up.

Entities:  

Mesh:

Year:  2005        PMID: 16234450      PMCID: PMC1772943          DOI: 10.1136/bjo.2005.072892

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


  17 in total

1.  Preservation of the eye in paranasal sinus cancer surgery.

Authors:  C Perry; P A Levine; B R Williamson; R W Cantrell
Journal:  Arch Otolaryngol Head Neck Surg       Date:  1988-06

2.  Orbital exenteration: a 13 year Manchester experience.

Authors:  I Rahman; A E Cook; B Leatherbarrow
Journal:  Br J Ophthalmol       Date:  2005-10       Impact factor: 4.638

3.  The role of orbital exenteration in choroidal melanoma with extrascleral extension.

Authors:  R C Kersten; D T Tse; R L Anderson; F C Blodi
Journal:  Ophthalmology       Date:  1985-03       Impact factor: 12.079

4.  Prognosis in uveal melanoma with extrascleral extension.

Authors:  J C Affeldt; D S Minckler; S P Azen; L Yeh
Journal:  Arch Ophthalmol       Date:  1980-11

Review 5.  Diagnosis and treatment of orbital invasion in uveal melanoma.

Authors:  Gonzalo Blanco
Journal:  Can J Ophthalmol       Date:  2004-06       Impact factor: 1.882

6.  Orbital exenteration at the Mayo Clinic. 1967-1986.

Authors:  G B Bartley; J A Garrity; R R Waller; J W Henderson; D M Ilstrup
Journal:  Ophthalmology       Date:  1989-04       Impact factor: 12.079

7.  The treatment of advanced choroidal melanoma with massive orbital extension.

Authors:  F J Rini; F A Jakobiec; A Hornblass; B L Beckerman; R L Anderson
Journal:  Am J Ophthalmol       Date:  1987-12-15       Impact factor: 5.258

8.  A 20-year series of orbital exenteration.

Authors:  P S Levin; J J Dutton
Journal:  Am J Ophthalmol       Date:  1991-11-15       Impact factor: 5.258

9.  Primary malignant neoplasms of the lacrimal gland.

Authors:  J E Wright; G E Rose; A Garner
Journal:  Br J Ophthalmol       Date:  1992-07       Impact factor: 4.638

10.  Prognostic factors in choroidal and ciliary body melanomas with extrascleral extension.

Authors:  J M Pach; D M Robertson; B S Taney; J A Martin; R J Campbell; P C O'Brien
Journal:  Am J Ophthalmol       Date:  1986-03-15       Impact factor: 5.258

View more
  8 in total

1.  Maggot therapy following orbital exenteration.

Authors:  Adrian Gericke; Esther M Hoffmann; Susanne Pitz; Norbert Pfeiffer
Journal:  Br J Ophthalmol       Date:  2007-12       Impact factor: 4.638

2.  Orbital exenteration for advanced periorbital non-melanoma skin cancer: prognostic factors and survival.

Authors:  R C Gerring; C T Ott; J M Curry; Z B Sargi; S T Wester
Journal:  Eye (Lond)       Date:  2016-10-21       Impact factor: 3.775

3.  Primary orbital rhabdomyosarcoma with skeletal muscle metastasis.

Authors:  Jayanta K Das; B K Tiwary; S B Paul; Harsha Bhattacharjee; Bhuyan Cida; Dipankar Das
Journal:  Oman J Ophthalmol       Date:  2010-05

4.  Vismodegib for Locally Advanced Periocular and Orbital Basal Cell Carcinoma: A Review of 15 Consecutive Cases.

Authors:  Kai Yuen Wong; Kate Fife; John T Lear; Richard D Price; Amer J Durrani
Journal:  Plast Reconstr Surg Glob Open       Date:  2017-07-21

5.  Clinico-Pathological Patterns of Patients Who Underwent Orbital Exenteration in a Tertiary Eye Hospital of Nepal.

Authors:  Limbu Ben; Mengesha Aemero; Anya G Gushchin; Grant H Moore; Saiju Rohit
Journal:  Ethiop J Health Sci       Date:  2016-11

6.  Selective Intra-Arterial Embolization for Advanced Extrascleral Uveal Melanoma.

Authors:  Víctor M Villegas; Mariola Monagas; Joseph Campbell; Timothy G Murray; Luis Serrano
Journal:  Ocul Oncol Pathol       Date:  2017-07-19

7.  A 12-year retrospective survey of management of patients with malignant neoplasms in the orbital cavity in a brazilian cancer hospital.

Authors:  Daniela Sirianni; Cláudio Rodrigues Leles; Elismauro Francisco Mendonça
Journal:  Open Dent J       Date:  2013-10-31

8.  Second primary malignancies of eye and ocular adnexa after a first primary elsewhere in the body.

Authors:  Ahmad Samir Alfaar; Anas M Saad; Mahmoud Tawfik KhalafAllah; Omneya Ezzat Elsherif; Moataz Hamed Osman; Olaf Strauß
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2020-09-01       Impact factor: 3.117

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.